Switch to a DOAC (Direct Oral Anticoagulant) Rather Than Discontinue Warfarin
In elderly patients with high fall risk requiring anticoagulation for stroke prevention, fall risk alone should not be a reason to discontinue warfarin—instead, switching to a DOAC (particularly apixaban) is the preferred strategy, as the stroke risk from withholding anticoagulation far exceeds the bleeding risk from falls.
The Fall Risk Myth
The concern about falls and anticoagulation is largely overestimated in clinical practice. A patient would need to fall approximately 295 times per year for the risk of subdural hematoma to outweigh the stroke prevention benefit of anticoagulation 1. This classic decision analysis demonstrates that even in patients at significant fall risk, anticoagulation remains beneficial across all age groups and baseline stroke risks 1.
The 2000 American Geriatrics Society guideline explicitly addresses this concern: balance problems and fall risk should be considered in the context of other factors (prior stroke, GI bleeding history, comorbidities), but are not absolute contraindications 2. The guideline emphasizes that physicians must weigh individual patient factors including the care setting, cognition, and caregiver availability—but fall risk alone does not justify withholding anticoagulation 2.
Why DOACs Are Superior in This Population
The most recent 2024 Chinese Expert Consensus Guidelines strongly recommend DOACs over warfarin for elderly patients with atrial fibrillation, including those at fall risk 3. The evidence is compelling:
- Meta-analysis of 22 studies confirmed that DOACs reduce stroke/systemic embolism, intracranial bleeding, hemorrhagic stroke, and fatal bleeding compared to warfarin in patients over 75 years 3
- Intracranial hemorrhage—the most devastating complication of falls on anticoagulation—is substantially lower with DOACs than warfarin 3
- The ChiOTEAF registry specifically documented that elderly patients with AF are often at fall risk, yet still benefit from optimal anticoagulation 3
Apixaban: The Preferred Choice
Among DOACs, apixaban demonstrates the most consistent benefit across frail, elderly, and fall-risk populations 4. The 2026 ACC Scientific Statement specifically recommends apixaban for frail individuals because it shows benefit across the full spectrum of frailty status with lower bleeding risk 4.
The 2026 COMBINE-AF substudy provides critical evidence: frail, elderly patients (≥75 years) switched from warfarin to standard-dose DOACs experienced significant reductions in stroke/systemic embolism, fatal bleeding, intracranial bleeding, and death 5. While gastrointestinal bleeding increased, the overall net clinical benefit favored DOACs 5.
Critical Dosing Considerations
Do not underdose DOACs out of fear—this increases mortality without reducing bleeding risk. The 2024 Chinese guidelines warn that very low-dose DOACs (edoxaban 15 mg, apixaban 2.5 mg, rivaroxaban 10 mg) in high-risk elderly patients were associated with:
- 54% increased arterial thrombosis risk
- 3.75-fold increased venous thrombosis risk
- 21% increased mortality 3
Use label-recommended dosing based on renal function, age, and weight 3. For patients truly unable to tolerate standard anticoagulation, low-dose edoxaban 15 mg daily can be considered as shown in ELDERCARE-AF (patients ≥80 years deemed unsuitable for standard anticoagulation) 4.
When Warfarin Must Be Continued
If switching to a DOAC is not feasible (mechanical valve, severe mitral stenosis, patient/insurance preference), optimize warfarin management:
- Target INR 1.6-2.5 for patients ≥75 years (lower than the standard 2.0-3.0 range) 3, 6, 3
- Aim for time in therapeutic range (TTR) ≥65% 3
- Ensure excellent blood pressure control—hypertension dramatically increases intracranial hemorrhage risk on warfarin 7
- More frequent INR monitoring may be needed in elderly patients due to greater fluctuations 8
Practical Implementation Algorithm
Assess stroke risk: Use CHA₂DS₂-VASc score. If ≥2 in males or ≥3 in females, anticoagulation is indicated regardless of fall risk 3
Evaluate bleeding risk factors (not fall risk alone):
- Prior major bleeding (especially GI or intracranial)
- Uncontrolled hypertension (systolic >160 mmHg)
- Severe renal impairment (CrCl <30 mL/min)
- Concurrent antiplatelet therapy
- Cognitive impairment affecting adherence
- Cerebral microbleeds on imaging 9
Switch to apixaban (first choice) or another DOAC:
- Apixaban 5 mg twice daily (or 2.5 mg twice daily if meets ≥2 criteria: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL)
- Check renal function before initiating and monitor regularly 3
Implement fall prevention strategies concurrently:
- Physical therapy/exercise programs
- Home safety assessment
- Medication review to reduce polypharmacy
- Vision and hearing optimization
- Treatment of orthostatic hypotension 9
Intensive follow-up: Monitor renal function, liver function, adherence, and cognitive status more frequently than in younger patients 3
When to Consider Deprescribing
Anticoagulation should only be discontinued in specific circumstances:
- Severe frailty with limited life expectancy (<6-12 months)
- Recurrent major bleeding despite optimal management
- Multiple cerebral microbleeds indicating high intracranial hemorrhage risk
- Patient/family preference after shared decision-making 9
The key pitfall is discontinuing anticoagulation based solely on fall risk—this denies patients proven stroke prevention benefit. The 2006 AHA/ASA guideline notes that age and fall risk are not contraindications to anticoagulation; the decision must incorporate the full clinical picture 7.
Common Pitfalls to Avoid
- Don't stop anticoagulation without switching to an alternative—the thromboembolic risk increases 2.2-2.5 fold without anticoagulation 3
- Don't arbitrarily reduce DOAC doses—underdosing increases mortality and thrombosis without reducing bleeding 3
- Don't switch stable elderly patients from well-controlled warfarin (TTR >70%) to DOACs without careful consideration—the FRAIL-AF trial showed early bleeding excess with switching 4, 5
- Don't forget to control blood pressure aggressively—this is critical for reducing intracranial hemorrhage risk on any anticoagulant 7
Document your shared decision-making discussion with the patient/family regarding risks and benefits, as this is essential for medicolegal protection and patient-centered care 2.